Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 462,023
  • Shares Outstanding, K 117,863
  • Annual Sales, $ 207,740 K
  • Annual Income, $ -143,590 K
  • 60-Month Beta 1.49
  • Price/Sales 2.30
  • Price/Cash Flow N/A
  • Price/Book 0.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.35
  • Number of Estimates 3
  • High Estimate -0.27
  • Low Estimate -0.41
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.73 +1.05%
on 07/18/19
5.00 -24.62%
on 07/01/19
-0.80 (-17.53%)
since 06/18/19
3-Month
3.73 +1.05%
on 07/18/19
6.78 -44.37%
on 04/23/19
-2.94 (-43.83%)
since 04/18/19
52-Week
3.73 +1.05%
on 07/18/19
10.73 -64.89%
on 07/19/18
-6.53 (-63.41%)
since 07/18/18

Most Recent Stories

More News
Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners

Akebia Therapeutics, Inc. (Nasdaq: AKBA) a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler,...

AKBA : 3.79 (-3.32%)
Akebia Therapeutics Announces Collaboration Partner's Positive Top-line Results of Phase 3 Clinical Study of Riona(R) (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan

Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco, Inc. (JT) and its subsidiary Torii Pharmaceutical Co., Ltd. (Torii), reported positive top-line...

TRXPF : 23.0200 (-2.04%)
AKBA : 3.79 (-3.32%)
Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board...

TRVN : 1.01 (-1.94%)
AKBA : 3.79 (-3.32%)
ACRS : 2.08 (-1.42%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14...

AKBA : 3.79 (-3.32%)
Akebia Therapeut Has Returned 29.2% Since SmarTrend Recommendation (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on April 4th, 2019 at $7.10. In approximately 2 months, Akebia Therapeut has returned 29.15% as of today's recent price of $5.03.

AKBA : 3.79 (-3.32%)
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced...

AKBA : 3.79 (-3.32%)
Downtrend Call Working As Akebia Therapeut Stock Falls 18.5% (AKBA)

SmarTrend identified a Downtrend for Akebia Therapeut (NASDAQ:AKBA) on April 4th, 2019 at $7.10. In approximately 1 month, Akebia Therapeut has returned 18.45% as of today's recent price of $5.79.

AKBA : 3.79 (-3.32%)
Akebia Therapeutics (AKBA) Reports Q1 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -4.76% and -13.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AKBA : 3.79 (-3.32%)
Akebia Therapeutics: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $72.4 million in its first quarter.

AKBA : 3.79 (-3.32%)
Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATEStudies and Announces Key Executive Appointments

--Full Enrollment of Phase 3 INNO2VATEStudies; and

AKBA : 3.79 (-3.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AKBA with:

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 4.18
1st Resistance Point 4.05
Last Price 3.79
1st Support Level 3.81
2nd Support Level 3.70

See More

52-Week High 10.73
Fibonacci 61.8% 8.06
Fibonacci 50% 7.23
Fibonacci 38.2% 6.41
Last Price 3.79
52-Week Low 3.73

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar